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review and calculated placebo-adjusted risk ratios for achieving good pain relief
(GPR), any adverse event (AE) and withdrawal owing to intolerable AE. Direct med-
ical costs included drug acquisition and additional visits due to lack of efficacy
(poor pain relief) or intolerable AE. Unit costs were taken from local sources. Ad-
herence rates (based in number of daily doses needed) were used to estimate the
expected drug costs. All costs are expressed in 2010 USD (1USD:12.50MXN Pesos).
Utility values drawn from published literature were applied to health states. Pro-
portion of patients with GPR and quality-adjusted life years (QALY) were assessed.
RESULTS: Branded-GBP was dominated by all the other options. PGB was more
costly and less effective than DUL. Compared with branded-GBP and PGB, DUL led
to savings of $80,080 and $85,920 (per 1000 patients) USD. The incremental cost per
QALY gained with DUL used instead of generic-GBP was $8,194. This amount is
slightly lower than the estimated gross domestic product per capita in Mexico for
2010. During a second-order Monte Carlo simulation, DUL had the highest proba-
bility of being cost-effective (61%), followed by generic-GBP (25%) and PGB (14%).
CONCLUSIONS: This study suggests that DUL provides overall savings and better
health outcomes compared with branded-GBP and PGB. Administering DUL rather
than generic-GBP is a highly cost-effective intervention to manage PDPN in Mexico.
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OBJECTIVES: Fragility fractures (FF) are associated with increased mortality, dete-
rioration in health-related quality of life and high costs. Teriparatide stimulates
bone remodeling. The aim of this study was to assess the cost and health effects of
teriparatide in women with postmenopausal osteoporosis (PMOP) and high risk of
FF from the perspective of public healthcare system in Mexico. METHODS: Target
population was women aged 70 years, with PMOP, T-score 4.0 and three clinical
risk factors, with a recent vertebral fracture not candidates to receive bisphospho-
nates. Competing alternatives were: (1) daily subcutaneous injection of teripa-
ratide 20mcg for 18 months and (2) no therapy. A Markov microsimulation model
was developed with a 30 years time horizon divided into 6-month cycles and is
composed by 5 health states: hip, vertebral, forearm and humerus fracture and
death. The incidence of FF was obtained from the FRAX® algorithms for Mexican
women. Efficacy data was gathered from placebo-controlled clinical trials of teripa-
ratide. We analyzed acquisition costs of teriparatide and medical care costs due to
FF. Frequency and location of fractures avoided and quality adjusted life years
(QALYs) were estimated. All costs are expressed in 2010 USD (1USD:12.50MXN
Pesos) RESULTS: Teriparatide avoided 324 FF per a thousand patients (hip: 43;
vertebral: 164; humerus: 35; forearm: 82). The number needed to treat (NNT) to
prevent one FF was 3.09. Teriparatide was slightly more expensive ($20,052 vs.
$22,209 USD) but more effective, with net gains of 87 QALYs per a thousand pa-
tients. The cost per additional QALY gained with teriparatide was $24,925 (below
the upper limit of 3 times the gross domestic product per capita in Mexico). Teripa-
ratide was found to be cost-effective therapy in 80% of the simulations performed
in the probabilistic sensitivity analysis. CONCLUSIONS: Teriparatide is a cost-ef-
fective intervention in women with PMOP and high risk of FF.
Gastrointestinal Disorders – Cost Studies
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OBJECTIVES: To assess health care resources use and costs associated with man-
agement of complex perianal fistula in Crohn’s disease (CPCD) in Spain.METHODS:
Multicenter, retrospective and observational study conducted by 13 gastroenterol-
ogists from 11 hospitals in the Autonomous Community of Madrid, Spain. Direct
healthcare resources consumption (pharmacological treatments, laboratory/diag-
nostic tests, visits to specialists, emergency department visits and hospitaliza-
tions/surgical procedures) were recorded for 97 adult patients with CPCD active at
some time between January 1, 2005 and study data collection (4.21.5 years).
RESULTS: 527 treatments were recorded: 73.1% pharmacological (32.3% antibiotics,
20.5% immunomodulators, 20.3% biological therapies) and 26.9% surgical. Mean
per patient-year global cost was €7821.4. Percentage cost per treatment type and
[mean per patient-year cost] breakdown was 78.7% [€5773.5] pharmacological cost,
11.12% [€1027.4] hospitalizations/surgical procedures, 6.5% [€640] specialists visits,
3.4 [€350] laboratory/diagnostic tests, and 0.2%, [€30.4] emergency department vis-
its. Mean per patient-year cost per pharmacological treatment type was: €12.5
antibiotics, €1050.6 immunomodulators, and €4710.4 biological therapies.
CONCLUSIONS: Pharmacological treatments are the main cost driver of CPCD
management in Spain, being biological therapies the main component. Study
funded by Cellerix, S.A. (Spain).
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OBJECTIVES: To estimate the cost-effectiveness of adalimumab CD treatment ver-
sus standard care and infliximab for patients with severe active CD. METHODS:
The model combines clinical, utility, and cost data. Four disease states (remission;
moderate; severe; very severe) based on the Crohn’s Disease Activity Index range
are used as measures of patient disease status. For the adalimumab arm, a cohort
for the proposed adalimumab regimen using actual observations from the EOW
arm in a randomized controlled clinical trial (CHARM) is used. For the standard care
arm, the model simulates patient disease states based on randomized controlled
trial data (CLASSIC I and CHARM) and calculates the probability of individuals
being in each disease state. The base-case model analyzes lifetime patient clinical
status. Hospitalization costs are estimated from the hospitalization unit cost and a
regression model based on CHARM trial data. Disease state specific non-hospital-
ization, non-anti TNF costs are summarized over time for each patient to include
other direct medical costs. For the adalimumab vs. infliximab model, the adali-
mumab regimen is compared to infliximab 5mg/kg maintenance therapy. The per-
centage of patients in remission over time is used as the measure of clinical effi-
cacy. Indirect costs are estimated based on hospitalization stays and post-
hospitalization recovery times. Costs are reported in Mexican Peso. RESULTS:
Compared to standard care, adalimumab is dominant for patients with severe CD
(cost difference -$16,825, gain in QALYs 0.1045). Adalimumab is dominant, with
lower costs and higher efficacy compared with infliximab when treating patients
with severe disease based on a societal perspective. Cost difference (adalimumab–
infliximab) were -$19,784, and including infliximab “overdosing”, the costs ac-
counted for -$42,356. Sensitivity analyses confirm the results obtained in the cost-
effectiveness analysis. CONCLUSIONS: Adalimumab maintenance therapy is
dominant over standard care. The adalimumab regimen is cost-saving over inflix-
imab 5mg/kg maintenance therapy.
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OBJECTIVOS: Mediante la adaptación a la realidad de Venezuela de un modelo
realizado por Spackman y Veenstra y previo análisis de transferibilidad, se realizó
un análisis de costo-efectividad del uso de 0.5 mg/día de entecavir versus inter-
ferón pegilado en la supresión de la replicación viral y la calidad de vida relacio-
nada con la salud en términos de QALYs en pacientes con Hepatitis B Crónica.
METODOLOGÍAS: Para la construcción de la cohorte hipotética, Spackman y Veen-
stra asumieron los datos de las eficacias así como las características de los pacien-
tes reportadas en estudios clínicos recientes. Para el análisis de transferibilidad se
siguieron los criterios de transferibilidad de la Task Force on Good Research Prac-
tices on Transferability of Economic Data de la ISPOR. En la adaptación del modelo
se asumieron las probabilidades de cambio entre estados reportadas en el estudio
original. Los costos médicos directos y de los medicamentos fueron tomados di-
rectamente del entorno local. Adicionalmente se tomaron las tablas de expectativa
de vida del observatorio de salud global de la Organización Mundial de la Salud para
Venezuela actualizadas al año 2008. Los resultados incluyeron los costos de cada
alternativa de tratamiento tanto con entecavir como con interferón pegilado, así
como los años de vida ajustados a calidad ganados. RESULTADOS: El entecavir 0.5
mg/día produjo 18,25 QALYs y una relación de costo efectividad media de 5.257 BsF
por QALY, en comparación con el interferón pegilado (marketshare) que produjo
18,12 QALYs y una relación de costo efectividad media de 7.055 BsF por QALY.
CONCLUSIONES: El entecavir a dosis de 0.5 mg/día mostró índices más bajos de
costo-efectividad media con respecto al interferón pegilado en la supresión viral en
pacientes con infección por el virus de la hepatitis B. En Venezuela, al igual que
muchos países latinoamericanos, no están establecidos umbrales de costo efectivi-
dad.
Gastrointestinal Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVES: MUSIC, an open-label, 1-year study of certolizumab pegol (CZP), eval-
uated the efficacy of CZP in improving pathological changes in the intestinal mu-
cosa of patients with active moderate-to-severe Crohn’s disease (CD). The purpose
of this posthoc study was to examine the relationship between CZP-mediated en-
doscopic improvement and changes in HRQoL in patients with CD. METHODS:
Patients with active CD (CD Activity Index score 225 to 450) were treated with
open-label CZP, 400 mg subcutaneously every 2 weeks for 3 doses (induction) then
400 mg every 4 weeks for up to 54 weeks (maintenance). Patients completed the
Inflammatory Bowel Disease Questionnaire (IBDQ) at baseline, Week 10, and Week
54 to assess HRQoL. An exploratory analysis of the correlation between IBDQ re-
mission (total score 170 points) and endoscopic remission (measured by a CD
Endoscopic Index of Severity score of 6 points) was performed. RESULTS: Of 89
patients entering the study, 78 patients at Week 10 and 50 patients at Week 54
completed the IBDQ. At baseline, mean IBDQ total score was 120.2. At Week 10,
mean change in IBDQ total score was 43.8 and the IBDQ remission rate was 43.8%.
At Week 54, mean change in IBDQ total score was 44.1 and the IBDQ remission rate
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